UNSPSC 51161571: Nivimedone sodium

This classification denotes a mast cell stabilizer with the molecular formula C11H8NO4.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4953C873N2, chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-), sodium, monohydrate but more generally known as nivimedone sodium, which bears US NIH Compound Identifier 43916. Most nations, for tariff and trade purposes, schedule nivimedone sodium under HS 29147000 and SITC 51629. As of Q4 2014, NIVIMEDONE SODIUM remains US FDA's Preferred Term for this commodity.

Nivimedone sodium bears US NLM identifiers UMLS ID C0132621 and NCI Concept Code C72941. SMILES: CC1CC2C(CC1C)C(=O)C(=[N+]([O-])[O-])C2=O.O.[NA+].

UNSPSC 51161571 Nivimedone sodium is a Commodity code for a specific pharmaceutical product that state and local government procurement offices acquire through cooperative purchasing agreements focused on generic multi-source pharmaceuticals and over-the-counter products for distribution across state facilities and participating jurisdictions. The work encompasses supply of FDA-compliant pharmaceutical products with specified National Drug Codes and packaging configurations, delivered through authorized wholesale distribution networks with established chargeback systems, pricing negotiation across multiple formats (flat price, net price variants, WAC-minus structures), and compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has posted the primary recent opportunity — a Request for Proposal issued January 20, 2026, seeking manufacturers for multi-source generic pharmaceuticals and OTC products to supply participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026 and awarded contracts effective July 1, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson Co., LLC), certify cGMP and DSCSA compliance, and carry comprehensive insurance including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Evaluation weights price competitiveness at 75 percent, with secondary weight on fixed pricing for contract term (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term runs two years for new vendors with optional extensions at MMCAP's discretion, with no stated set-aside designations disclosed in available documentation.